New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
11:38 EDTGALT, CYTK, ATHNOptions with increasing implied volatility: CYTK GALT ATHN
News For CYTK;GALT;ATHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 1, 2015
12:12 EDTATHNathenahealth weakness today a buying opportunity, says Piper Jaffray
Subscribe for More Information
April 30, 2015
19:01 EDTATHNOn The Fly: After Hours Movers
UP AFTER EARNINGS: Ellie Mae (ELLI), up 10%... Ocwen Financial (OCN), up 9%... athenahealth (ATHN), up 8.5%... Expedia (EXPE), up 4.5%... Skyworks Solutions (SWKS), up 3.7%... Eastman Chemical (EMN), up 2.4%... Nektar Therapeutics (NKTR), up 1.4%... FireEye (FEYE), up 2%. ALSO HIGHER: Monsanto (MON), up 3.6% following a Bloomberg report that the company approached Syngenta (SYT) about a takeover... Altera (ALTR), up 4.4% following a Reuters report that Intel (INTC) has a standstill pact set to end in June. DOWN AFTER EARNINGS: LinkedIn (LNKD), down 21.3%... Hutchinson Technology (HTCH), down 15.3%... Insulet (PODD), down 13.9%... Accuray (ARAY), down 14%... Constant Contact (CTCT), down 9.9%... Trimble Navigation (TRMB), down 6.6%... First Solar (FSLR), down 4.4%... JDS Uniphase (JDSU), down 3%... BioMarin (BMRN), down 1.8%... Visa (V), down 1.6%.
16:22 EDTATHNathenahealth backs FY15 adjusted EPS view $1.10-$1.20, consensus $1.16
Backs FY15 revenue view $905M-$925M, consensus $919.74M.
16:21 EDTATHNathenahealth reports Q1 adjusted EPS 24c, consensus 14c
Reports Q1 revenue $206.4M, consensus $205.13M.
16:19 EDTCYTKCytokinetics sees initiating phase 3 tirasemtiv program in Q2
Cytokinetics (CYTK) expects to initiate a phase III clinical development program for tirasemtiv in patients with ALS in Q2. Cytokinetics expects to initiate a phase II trial of CK-2127107 in patients with SMA in 2H. Cytokinetics expects results from COSMIC-HF to be available in 2H. Cytokinetics expects to continue joint development activities in collaboration with Amgen (AMGN) directed to the potential advancement of omecamtiv mecarbil to phase III clinical development.
16:17 EDTCYTKCytokinetics reports Q1 EPS (23c), may not compare to consensus (12c)
Reports Q1 revenue $4.41M, may not compare to consensus $10.08M.
15:01 EDTATHNNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Visa (V), consensus 62c... Gilead Sciences (GILD), consensus $2.32... American International (AIG), consensus $1.19... Public Storage (PSA), consensus $1.93... LinkedIn (LNKD), consensus 56c... BioMarin Pharmaceutical (BMRN), consensus (53c)... Expedia (EXPE), consensus 9c... Skyworks Solutions (SWKS), consensus $1.13... FleetCor (FLT), consensus $1.40... Eastman Chemical (EMN), consensus $1.60... Western Union (WU), consensus 38c... Fluor (FLR), consensus 98c... Fortune Brands Home & Security (FBHS), consensus 32c... Envision Healthcare (EVHC), consensus 26c... Agnico Eagle Mines (AEM), consensus 10c... FireEye (FEYE), consensus (51c)... Trimble Navigation (TRMB), consensus 30c... PerkinElmer (PKI), consensus 46c... Genpact (G), consensus 25c... athenahealth (ATHN), consensus 14c... Seattle Genetics (SGEN), consensus (19c)... HEALTHSOUTH (HLS), consensus 56c... Teradyne (TER), consensus 12c... Superior Energy (SPN), consensus (5c)... Eldorado Gold (EGO), consensus 2c... Regal Entertainment (RGC), consensus 12c... JDS Uniphase (JDSU), consensus 9c... MRC Global (MRC), consensus 18c... Boyd Gaming (BYD), consensus 9c... Ruckus Wireless (RKUS), consensus 8c... Cloud Peak Energy (CLD), consensus (12c).
April 26, 2015
13:41 EDTATHNShares of athenahealth could fall to $80, Barron's says
Subscribe for More Information
April 23, 2015
07:07 EDTGALTRedChip to hold a virtual conference
Subscribe for More Information
April 22, 2015
07:16 EDTGALTRedChip to hold a virtual conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use